Andrey Loboda
Andrey Loboda has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
- Philip E. Brandish
Bicycle Therapeutics, Inc 35 Cambridgepark Drive Suite 350 02140 Cambridge MA USA and
31 shared publications - Razvan Cristescu
Merck
30 shared publications - Handan Xiang
Discovery Immunology, Merck & Co., Inc., Rahway, NJ 07065, USA
28 shared publications - Josephine Hai
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
28 shared publications - Lily Y. Moy
Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
28 shared publications - Marc A. Sze
Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA
28 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors
Purpose: Interleukin 4 induced 1 (IL4I1) is an immunometabolic enzyme with an immunosuppressive role in the tumor microenvironment. High IL4I1 expression is associated with suppressed antitumor immunity and enhanced metastasis. MK-6598 is a novel, small-molecule inhibitor of IL4I1. This first-in-human study evaluated MK-6598 with or without pembrolizumab in previously treated advanced solid tumors (NCT05594043). Patients and methods: Participants received prespecified, escalating doses of MK-6598 (50, 125, 250, and 500 mg) orally once daily with or without pembrolizumab 200 mg intravenously every 3 weeks. Primary objectives were safety and tolerability. Secondary objectives included the pharmacodynamics of MK-6598; tertiary/exploratory objectives included efficacy endpoints and response biomarker analyses. Results: Thirty-nine participants were enrolled (MK-6598, n=20; MK-6598 plus pembrolizumab, n=19). MK-6598 monotherapy dose escalation was completed with no dose-limiting toxicities (DLTs). Three DLTs occurred in the MK-6598 plus pembrolizumab arm (grade 3 maculopapular rash, n=1 [MK-6598 50 mg]; grade 3 Stevens-Johnson syndrome, n=1 [MK-6598 250 mg]; grade 1 fever and grade 1 influenza-like illness leading to dose delay, n=1 [MK-6598 250 mg]). No fatal treatment-related adverse events occurred. Tumor phenylpyruvate concentrations, per on-treatment biopsy, decreased across all dose levels. Higher tumor IL4I1 expression was associated with higher baseline phenylpyruvate concentration and larger decreases in phenylpyruvate concentration from baseline to day 1 of cycle 2. There were no confirmed responses per RECIST version 1.1 by investigator assessment in either cohort. Conclusions: MK-6598 had a manageable safety profile and demonstrated target engagement when given as monotherapy or in combination with pembrolizumab but had limited antitumor activity.
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Open AccessA First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors
Purpose: Interleukin 4 induced 1 (IL4I1) is an immunometabolic enzyme with an immunosuppressive role in the tumor microenvironment. High IL4I1 expression is associated with suppressed antitumor immunity and enhanced metastasis. MK-6598 is a novel, small-molecule inhibitor of IL4I1. This first-in-human study evaluated MK-6598 with or without pembrolizumab in previously treated advanced solid tumors (NCT05594043). Patients and methods: Participants received prespecified, escalating doses of MK-6598 (50, 125, 250, and 500 mg) orally once daily with or without pembrolizumab 200 mg intravenously every 3 weeks. Primary objectives were safety and tolerability. Secondary objectives included the pharmacodynamics of MK-6598; tertiary/exploratory objectives included efficacy endpoints and response biomarker analyses. Results: Thirty-nine participants were enrolled (MK-6598, n=20; MK-6598 plus pembrolizumab, n=19). MK-6598 monotherapy dose escalation was completed with no dose-limiting toxicities (DLTs). Three DLTs occurred in the MK-6598 plus pembrolizumab arm (grade 3 maculopapular rash, n=1 [MK-6598 50 mg]; grade 3 Stevens-Johnson syndrome, n=1 [MK-6598 250 mg]; grade 1 fever and grade 1 influenza-like illness leading to dose delay, n=1 [MK-6598 250 mg]). No fatal treatment-related adverse events occurred. Tumor phenylpyruvate concentrations, per on-treatment biopsy, decreased across all dose levels. Higher tumor IL4I1 expression was associated with higher baseline phenylpyruvate concentration and larger decreases in phenylpyruvate concentration from baseline to day 1 of cycle 2. There were no confirmed responses per RECIST version 1.1 by investigator assessment in either cohort. Conclusions: MK-6598 had a manageable safety profile and demonstrated target engagement when given as monotherapy or in combination with pembrolizumab but had limited antitumor activity.
- Top Cited PapersOpen Access
- 1 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3475-3484
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
At the first interim analysis of the phase 3 KEYNOTE-426 trial, first-line pembrolizumab plus axitinib showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) over sunitinib for advanced renal cell carcinoma (RCC). To assess long-term durability of clinical outcomes and elucidate predictive biomarkers for RCC, we performed efficacy and prespecified exploratory biomarker analyses from KEYNOTE-426 with ≥5 years of follow-up. Pembrolizumab plus axitinib showed sustained benefits in OS (hazard ratio: 0.84; 95% confidence interval: 0.71–0.99), PFS (hazard ratio: 0.69; 95% confidence interval: 0.59–0.81) and ORR (60.6% versus 39.6%) compared to sunitinib. An 18-gene T-cell-inflamed gene expression profile (TcellinfGEP) was positively associated with OS (P = 0.002), PFS (P < 0.0001) and ORR (P < 0.0001) within the pembrolizumab plus axitinib arm. An angiogenesis signature was positively associated with OS (P = 0.004) within the pembrolizumab plus axitinib arm and with OS (P < 0.0001), PFS (P < 0.001) and ORR (P = 0.002) within the sunitinib arm. Across arms, programmed cell death ligand 1 combined positive score was only associated (negatively) with OS within the sunitinib arm (P = 0.025). Additionally, PBRM1 (polybromo-1) mutation had a positive association with ORR (P = 0.002) within the pembrolizumab plus axitinib arm. Within the sunitinib arm, OS was positively associated with VHL (von Hippel–Lindau tumor suppressor gene) (P = 0.040) and PBRM1 (P = 0.010) mutations and was negatively associated with BAP1 (BRCA1-associated protein 1) mutation (P = 0.019). Results showed a sustained clinical benefit with pembrolizumab plus axitinib over sunitinib and provide valuable information on biomarkers for immunotherapy-based treatment combinations in advanced RCC. Prospective clinical investigations are needed for biomarker-directed treatment for advanced RCC. ClinicalTrials.gov identifier: NCT02853331.
- 1 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3475-3484
Top Cited PapersOpen AccessPembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
At the first interim analysis of the phase 3 KEYNOTE-426 trial, first-line pembrolizumab plus axitinib showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) over sunitinib for advanced renal cell carcinoma (RCC). To assess long-term durability of clinical outcomes and elucidate predictive biomarkers for RCC, we performed efficacy and prespecified exploratory biomarker analyses from KEYNOTE-426 with ≥5 years of follow-up. Pembrolizumab plus axitinib showed sustained benefits in OS (hazard ratio: 0.84; 95% confidence interval: 0.71–0.99), PFS (hazard ratio: 0.69; 95% confidence interval: 0.59–0.81) and ORR (60.6% versus 39.6%) compared to sunitinib. An 18-gene T-cell-inflamed gene expression profile (TcellinfGEP) was positively associated with OS (P = 0.002), PFS (P < 0.0001) and ORR (P < 0.0001) within the pembrolizumab plus axitinib arm. An angiogenesis signature was positively associated with OS (P = 0.004) within the pembrolizumab plus axitinib arm and with OS (P < 0.0001), PFS (P < 0.001) and ORR (P = 0.002) within the sunitinib arm. Across arms, programmed cell death ligand 1 combined positive score was only associated (negatively) with OS within the sunitinib arm (P = 0.025). Additionally, PBRM1 (polybromo-1) mutation had a positive association with ORR (P = 0.002) within the pembrolizumab plus axitinib arm. Within the sunitinib arm, OS was positively associated with VHL (von Hippel–Lindau tumor suppressor gene) (P = 0.040) and PBRM1 (P = 0.010) mutations and was negatively associated with BAP1 (BRCA1-associated protein 1) mutation (P = 0.019). Results showed a sustained clinical benefit with pembrolizumab plus axitinib over sunitinib and provide valuable information on biomarkers for immunotherapy-based treatment combinations in advanced RCC. Prospective clinical investigations are needed for biomarker-directed treatment for advanced RCC. ClinicalTrials.gov identifier: NCT02853331.
- Open Access
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400456
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
PURPOSE: The Cancer Genome Atlas (TCGA) classifies gastric cancer (GC) into four molecular subtypes: Epstein-Barr virus–positive, microsatellite instability–high (MSI-H), genomically stable (GS), and chromosomal instability (CIN). This exploratory analysis compared the genomic landscape of late-stage GC from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies with early-stage GC from TCGA and evaluated the genomic characteristics of late-stage GC in patients of Western and Asian origin. MATERIALS AND METHODS: Using pretreatment tumor samples, bulk DNA was analyzed via whole-exome sequencing (WES; KEYNOTE-059/KEYNOTE-061) and FoundationOneCDx (KEYNOTE-062) to determine TCGA-defined molecular subtypes (only MSI-H is determinable from FoundationOneCDx), genomic alterations, homologous recombination deficiency (HRD), and tumor mutational burden (TMB); gene expression signatures were analyzed using RNA sequencing. RESULTS: When comparing KEYNOTE-059/061/062 combined WES and FoundationOneCDx data with data from TCGA, the MSI-H subtype prevalence was numerically lower in patients of Western (5% v 22%) and Asian origin (5% v 19%). When comparing KEYNOTE-059/061 WES data with the TCGA data set, the GS subtype prevalence was numerically higher (36% v 21%) in patients of Western or Asian origin. Among subtypes in KEYNOTE-059/061, HRD scores and TMB trended highest in CIN and MSI-H subtypes, respectively. TP53 mutation was the most prevalent genomic characteristic per KEYNOTE-059/061/062 combined analysis in patients of Western or Asian origin. Gene expression signature distributions were generally similar between patients of Western and Asian origin. CONCLUSION: Numerical differences in the prevalence of MSI-H and GS subtypes were observed between early-stage and late-stage GC. Genomic characteristics of late-stage GC were generally similar between patients of Western and Asian origin.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400456
Open AccessGenomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
PURPOSE: The Cancer Genome Atlas (TCGA) classifies gastric cancer (GC) into four molecular subtypes: Epstein-Barr virus–positive, microsatellite instability–high (MSI-H), genomically stable (GS), and chromosomal instability (CIN). This exploratory analysis compared the genomic landscape of late-stage GC from KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 studies with early-stage GC from TCGA and evaluated the genomic characteristics of late-stage GC in patients of Western and Asian origin. MATERIALS AND METHODS: Using pretreatment tumor samples, bulk DNA was analyzed via whole-exome sequencing (WES; KEYNOTE-059/KEYNOTE-061) and FoundationOneCDx (KEYNOTE-062) to determine TCGA-defined molecular subtypes (only MSI-H is determinable from FoundationOneCDx), genomic alterations, homologous recombination deficiency (HRD), and tumor mutational burden (TMB); gene expression signatures were analyzed using RNA sequencing. RESULTS: When comparing KEYNOTE-059/061/062 combined WES and FoundationOneCDx data with data from TCGA, the MSI-H subtype prevalence was numerically lower in patients of Western (5% v 22%) and Asian origin (5% v 19%). When comparing KEYNOTE-059/061 WES data with the TCGA data set, the GS subtype prevalence was numerically higher (36% v 21%) in patients of Western or Asian origin. Among subtypes in KEYNOTE-059/061, HRD scores and TMB trended highest in CIN and MSI-H subtypes, respectively. TP53 mutation was the most prevalent genomic characteristic per KEYNOTE-059/061/062 combined analysis in patients of Western or Asian origin. Gene expression signature distributions were generally similar between patients of Western and Asian origin. CONCLUSION: Numerical differences in the prevalence of MSI-H and GS subtypes were observed between early-stage and late-stage GC. Genomic characteristics of late-stage GC were generally similar between patients of Western and Asian origin.
- Open Access
Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer
Background Over a century ago, Virchow proposed that cancer represents a chronically inflamed, poorly healing wound. Normal wound healing is represented by a transitory phase of inflammation, followed by a pro-resolution phase, with prostaglandin (PGE2/PGD2)-induced ‘lipid class switching’ producing inflammation-quenching lipoxins (LXA4, LXB4). Objective We explored if lipid dysregulation in colorectal cancers (CRCs) is driven by a failure to resolve inflammation. Design We performed liquid chromatography and tandem mass spectrometry (LC–MS/MS) untargeted analysis of 40 human CRC and normal paired samples and targeted, quantitative analysis of 81 human CRC and normal paired samples. We integrated analysis of lipidomics, quantitative reverse transcription-PCR, large scale gene expression, and spatial transcriptomics with public scRNASEQ data to characterize pattern, expression and cellular localisation of genes that produce and modify lipid mediators. Results Targeted, quantitative LC–MS/MS demonstrated a marked imbalance of pro-inflammatory mediators, with a dearth of resolving lipid mediators. In tumours, we observed prominent over-expression of arachidonic acid derivatives, the genes encoding their synthetic enzymes and receptors, but poor expression of genes producing pro-resolving synthetic enzymes and resultant lipoxins (LXA4, LXB4) and associated receptors. These results indicate that CRC is the product of defective lipid class switching likely related to inadequate or ineffective levels of PGE2/PGD2. Conclusion We show that the lipidomic profile of CRC tumours exhibits a distinct pro-inflammatory bias with a deficiency of endogenous resolving mediators secondary to defective lipid class switching. These observations pave the way for ‘resolution medicine’, a novel therapeutic approach for inducing or providing resolvins to mitigate the chronic inflammation driving cancer growth and progression.
Open AccessIntegration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer
Background Over a century ago, Virchow proposed that cancer represents a chronically inflamed, poorly healing wound. Normal wound healing is represented by a transitory phase of inflammation, followed by a pro-resolution phase, with prostaglandin (PGE2/PGD2)-induced ‘lipid class switching’ producing inflammation-quenching lipoxins (LXA4, LXB4). Objective We explored if lipid dysregulation in colorectal cancers (CRCs) is driven by a failure to resolve inflammation. Design We performed liquid chromatography and tandem mass spectrometry (LC–MS/MS) untargeted analysis of 40 human CRC and normal paired samples and targeted, quantitative analysis of 81 human CRC and normal paired samples. We integrated analysis of lipidomics, quantitative reverse transcription-PCR, large scale gene expression, and spatial transcriptomics with public scRNASEQ data to characterize pattern, expression and cellular localisation of genes that produce and modify lipid mediators. Results Targeted, quantitative LC–MS/MS demonstrated a marked imbalance of pro-inflammatory mediators, with a dearth of resolving lipid mediators. In tumours, we observed prominent over-expression of arachidonic acid derivatives, the genes encoding their synthetic enzymes and receptors, but poor expression of genes producing pro-resolving synthetic enzymes and resultant lipoxins (LXA4, LXB4) and associated receptors. These results indicate that CRC is the product of defective lipid class switching likely related to inadequate or ineffective levels of PGE2/PGD2. Conclusion We show that the lipidomic profile of CRC tumours exhibits a distinct pro-inflammatory bias with a deficiency of endogenous resolving mediators secondary to defective lipid class switching. These observations pave the way for ‘resolution medicine’, a novel therapeutic approach for inducing or providing resolvins to mitigate the chronic inflammation driving cancer growth and progression.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
The marker genes identified in endothelial cell clusters
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
The marker genes identified in endothelial cell clusters
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Spearman Correlation Between NOTCH3 Expression and global genes, angiogenesis gene signature, and stroma_EMT_TGFbeta gene signature in TCGA and Collaboration dataset
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Spearman Correlation Between NOTCH3 Expression and global genes, angiogenesis gene signature, and stroma_EMT_TGFbeta gene signature in TCGA and Collaboration dataset
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Annotation of the cell clusters identified by IMC
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Annotation of the cell clusters identified by IMC
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
The marker genes identified in endothelial cell clusters
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
The marker genes identified in endothelial cell clusters
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Supplementary Figures with legend
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
Supplementary Figures with legend
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
ScRNA-seq gene expression of mesenchymal cells
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma
ScRNA-seq gene expression of mesenchymal cells